TMS has 11 investors including 77 Capital And Nissay Capital.

TMS - Crunchbase Company Profile & Funding

Q: Where is TMS's headquarters?

TMS is located in Fuchu, Tokyo, Japan.

Q: When was the last funding round for TMS?

TMS closed its last funding round on obfuscated from a Venture - Series Unknown round.

Overview

TMS

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About TMS

CB Rank

56317

TMS is a clinical-stage biotech company that develops pharmaceuticals, quasi-drugs, raw materials, medical devices, and consumables.

Founded

obfuscation

Public

Venture - Series Unknown

Fuchu, Tokyo, Japan

11-50

www.tms-japan.co.jp

Biotechnology

Life Science

Medical

Nursing and Residential Care

Pharmaceutical

Funding Rounds

Venture - Series Unknown

OBF

obfuscation

Series C

OBF

obfuscation

Convertible Note

OBF

obfuscation

Key People

Takuro Wakabayashi: CEO
Ken Takanashi: Director

Details

Legal Name

TMS Co., Ltd.

Also Known As

ティムス

Operating Status

Active

Stock Symbol

TYO:4891

Company Type

For Profit

Founders

Keiji Hasumi

About the Company

TMS is a Tokyo-based clinical-stage biotech company that unlocks fungus-derived SMTP small molecule compound group. SMTPs have novel dual mode of action, both thrombolytic and anti-inflammatory. The lead compound TMS-007 is in Phase IIa clinical trial indicated for acute ischemic stroke and partnered with Biogen.

Phone Number

+81 42-306-5087

Contact Email

info@tms-japan.co.jp

Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

TMS-007

A small molecule drug candidate for treating acute ischemic stroke, developed through clinical trials and partnered with Biogen.

TMS-008

A small molecule compound with anti-inflammatory and antioxidative properties, under development for acute kidney injury and cancer cachexia.

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Venture Round - TMS	1	obfuscated obfuscation	77 Capital	Venture - Series Unknown
obfuscated obfuscation	Venture Round - TMS	1	obfuscated obfuscation	77 Capital	Venture - Series Unknown
obfuscated obfuscation	Venture Round - TMS	1	obfuscated obfuscation	77 Capital	Venture - Series Unknown
obfuscated obfuscation	Venture Round - TMS	1	obfuscated obfuscation	77 Capital	Venture - Series Unknown
obfuscated obfuscation	Venture Round - TMS	1	obfuscated obfuscation	77 Capital	Venture - Series Unknown

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Venture Round - TMS	1	obfuscated obfuscation	77 Capital	Venture - Series Unknown
obfuscated obfuscation	Venture Round - TMS	1	obfuscated obfuscation	77 Capital	Venture - Series Unknown
obfuscated obfuscation	Venture Round - TMS	1	obfuscated obfuscation	77 Capital	Venture - Series Unknown
obfuscated obfuscation	Venture Round - TMS	1	obfuscated obfuscation	77 Capital	Venture - Series Unknown
obfuscated obfuscation	Venture Round - TMS	1	obfuscated obfuscation	77 Capital	Venture - Series Unknown

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
77 Capital	Yes	Venture Round - TMS	—
77 Capital	Yes	Venture Round - TMS	—
77 Capital	Yes	Venture Round - TMS	—
77 Capital	Yes	Venture Round - TMS	—
77 Capital	Yes	Venture Round - TMS	—